Myokardia Inc (OQ:MYOK)

Nov 27, 2019 08:00 am ET
MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 2nd  Annual HealthCONx Conference on Wednesday, December 4th, 2019, at 10:15 a.m. ET in Boston,...
Nov 11, 2019 07:30 am ET
MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten
MyoKardia, Inc. (Nasdaq: MYOK) today announced new data from the company’s PIONEER open-label extension (OLE) study of mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Data for twelve patients at 48 weeks...
Nov 11, 2019 07:30 am ET
MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten
MyoKardia, Inc. (Nasdaq: MYOK), today announced topline data from MAVERICK-HCM, the company’s Phase 2 clinical trial of mavacamten in patients with non-obstructive hypertrophic cardiomyopathy (HCM).  The study achieved its primary objective of...
Nov 06, 2019 04:05 pm ET
MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Credit Suisse 28th Annual Healthcare Conference on Wednesday, November 13th, 2019, at 9:45 a.m. MT (11:45...
Nov 04, 2019 04:44 pm ET
MyoKardia Reports Third Quarter 2019 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019. “As we look across the milestones recently achieved and those just ahead, we see steady progress on our near- and long-term corporate...
Nov 04, 2019 08:30 am ET
MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019
MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA) Scientific Sessions taking place November 16 – November 18, 2019 in Philadelphia, Pennsylvania. The abstracts...
Oct 28, 2019 08:30 am ET
MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population
MyoKardia, Inc. (Nasdaq: MYOK), today announced positive interim data from the company’s Phase 2a clinical trial of MYK-491 and will advance MYK-491 into a Phase 2 study in patients with genetic dilated cardiomyopathy (DCM). MYK-491 is MyoKardia’s...
Sep 26, 2019 04:05 pm ET
MyoKardia to Present at 2019 Cantor Global Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019, at 4:10 p.m. ET in New York, NY. A...
Sep 10, 2019 08:44 am ET
MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients
MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study will be conducted at leading HCM centers that regularly perform surgical myectomy or alcohol...
Aug 31, 2019 05:00 am ET
MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019
MyoKardia, Inc. (Nasdaq: MYOK) today presented positive data from the company’s PIONEER open-label extension (OLE) study of mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM) at the European Society of...
Aug 28, 2019 04:05 pm ET
MyoKardia to Participate in September Investor Conferences
MyoKardia, Inc. (Nasdaq: MYOK), today announced its participation in the following upcoming investor conferences: Citi 14th Annual Biotech Conference in Boston, MA on Wednesday, September 4, 2019.2019 Wells Fargo Healthcare Conference in Boston,...
Aug 26, 2019 08:30 am ET
MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019
MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC) Congress taking place August 31 – September 4, 2019 in Paris, France. Among the highlights of the data being...
Aug 21, 2019 08:30 am ET
MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy (HCM). HCM is a progressive...
Aug 15, 2019 08:30 am ET
MyoKardia Launches 2nd Annual MyoSeeds™ Research Grants Program to Advance Independent Research in Heart Disease
MyoKardia, Inc. today announced the launch of the 2nd Annual MyoSeeds™ Research Grants Program, an initiative to support original, independent research in the biology and underlying mechanisms of cardiomyopathies and precision heart disease...
Aug 07, 2019 04:05 pm ET
MyoKardia Reports Second Quarter 2019 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the second quarter ended June 30, 2019. “We are now less than a year away from potentially game-changing pivotal data from our EXPLORER-HCM clinical trial of mavacamten in...
Aug 07, 2019 08:00 am ET
MyoKardia to Present at 2019 Wedbush PacGrow Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14th, 2019, at 10:55 a.m. ET in New York, NY. A webcast of the...
Jul 31, 2019 04:05 pm ET
MyoKardia to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter 2019 financial and operating results on Wednesday, August 7, 2019. Management will host a conference call and live audio webcast to discuss these results and provide...
Jul 18, 2019 08:30 am ET
MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
MyoKardia, Inc. (Nasdaq: MYOK) today announced updates related to its hypertrophic cardiomyopathy (HCM) treatment portfolio, including lead therapeutic candidate, mavacamten.  Patient screening has closed for the Phase 3 EXPLORER-HCM...
Jun 24, 2019 08:30 am ET
MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK) today announced the publication of an article titled, “Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy (oHCM) Using a Wearable Biosensor,” in the Nature Partner Journal, Digital Medicine. This...
Jun 18, 2019 04:05 pm ET
MyoKardia to Present at 2019 BMO Prescriptions for Success Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that Jake Bauer, Chief Business Officer, will participate in a...
May 28, 2019 08:30 am ET
MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece
MyoKardia, Inc., (Nasdaq: MYOK), presented data today at the European Society of Cardiology Heart Failure Congress from its Phase 1a single-ascending dose study of MYK-491 in healthy volunteers. MYK-491 is MyoKardia’s most advanced activator...
May 09, 2019 04:05 pm ET
MyoKardia Reports First Quarter 2019 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the quarter ended March 31, 2019....
May 08, 2019 04:10 pm ET
MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will...
May 07, 2019 04:10 pm ET
MyoKardia Announces Inaugural MyoSeeds™ Research Grants Program Awardees
MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced the award of $750,000 divided among three innovative research projects through the first cycle...
May 02, 2019 08:00 am ET
MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it will report first quarter 2019 financial and operating...
Apr 30, 2019 08:30 am ET
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the publication of results from the company’s Phase 2...
Mar 27, 2019 07:30 am ET
Detailed Research: Economic Perspectives on TIER REIT, MyoKardia, Radian Group, Packaging Corporation of America, Air Products and Chemicals, and ProAssurance — What Drives Growth in Today's Competiti
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TIER REIT, Inc. (NYSE:TIER), MyoKardia, Inc. (NASDAQ:MYOK), Radian...
Mar 26, 2019 06:45 pm ET
MyoKardia Announces Pricing of Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 4,925,000...
Mar 25, 2019 04:01 pm ET
MyoKardia Announces Proposed Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering...
Mar 06, 2019 08:00 am ET
MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the...
Mar 04, 2019 08:02 am ET
MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced positive 12- and 24-week safety, efficacy and biomarker data...
Feb 28, 2019 08:30 am ET
MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the fourth quarter and full year ended...
Feb 04, 2019 08:15 am ET
Market Trends Toward New Normal in Duke Energy, VICI Properties, MyoKardia, FLIR, TIER REIT, and ChannelAdvisor — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Duke Energy Corporation (NYSE:DUK), VICI Properties Inc. (NYSE:VICI),...
Jan 23, 2019 08:30 am ET
MyoKardia Appoints William Fairey as Chief Commercial Officer
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as Chief Commercial...
Jan 03, 2019 08:00 am ET
MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 37th Annual...
Jan 02, 2019 08:00 am ET
MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered under its license and...
Dec 11, 2018 08:30 am ET
MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced topline results from the Phase 1b single-ascending dose study of MYK-491....
Dec 05, 2018 04:01 pm ET
MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Taylor Harris, Chief Financial Officer, will present at the BMO 2018...
Nov 28, 2018 08:55 am ET
Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MyoKardia, Inc. (NASDAQ:MYOK), Bristow Group Inc (NYSE:BRS), The Chefs'...
Nov 12, 2018 07:30 am ET
MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, presented preclinical data at the American Heart Association (AHA) Scientific Sessions 2018 that...
Nov 07, 2018 04:30 pm ET
MyoKardia Reports Third Quarter 2018 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018.  “MyoKardia continues...
Nov 07, 2018 08:01 am ET
MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer, will provide a corporate...
Nov 05, 2018 08:00 am ET
MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced the presentation of twelve abstracts at the upcoming American Heart Association...
Nov 05, 2018 08:00 am ET
MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced new clinical data describing mavacamten’s effect on diastolic function will be...
Oct 30, 2018 07:30 am ET
MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day
MyoKardia, Inc., (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, announced a comprehensive update on its clinical-stage and emerging pipeline today at its 2018...
Oct 25, 2018 12:00 am ET
MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe
MyoKardia, Inc., (Nasdaq: MYOK), a clinical stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it has entered into a collaboration with 23andMe to advance research for...
Oct 24, 2018 04:30 pm ET
MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that patient dosing has begun in the MAVA Long-Term Extension (MAVA-LTE) clinical...
Oct 22, 2018 08:30 am ET
MyoKardia to Host R&D Day on October 30, 2018
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it will host a Research and Development (R) Day for analysts and investors...
Oct 19, 2018 08:30 am ET
Recent Analysis Shows Vipshop, MyoKardia, HudBay Minerals, Nordic American Tankers, Yum China, and TIM Participacoes S.A. Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Vipshop Holdings Limited (NYSE:VIPS), MyoKardia, Inc. (NASDAQ:MYOK),...
Sep 24, 2018 08:01 am ET
MyoKardia to Present at the 2018 Cantor Global Healthcare Conference
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 2018 Cantor...
Aug 29, 2018 04:01 pm ET
MyoKardia to Present at Two Upcoming Investor Conferences in September
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that senior company management will be participating in the following upcoming...
Aug 23, 2018 08:00 am ET
New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation
The Sarcomeric Human Cardiomyopathy Registry (SHaRe) and MyoKardia, Inc. (Nasdaq: MYOK) announced today the publication of results from a multicenter, international, longitudinal study of data from nearly 4,600 patients with hypertrophic...
Aug 21, 2018 07:30 am ET
Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alamos Gold Inc. (NYSE:AGI), Nomad Foods Limited (NYSE:NOMD), MyoKardia,...
Aug 08, 2018 04:02 pm ET
MyoKardia Reports Second Quarter 2018 Financial Results
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended June 30, 2018.  “This quarter saw...
Aug 07, 2018 04:01 pm ET
MyoKardia to Present at the 2018 Wedbush Pacgrow Healthcare Conference
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer,  will...
Aug 01, 2018 04:30 pm ET
MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report second quarter 2018 financial and...
Jun 26, 2018 08:30 am ET
MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the company’s Phase...
Jun 06, 2018 08:30 am ET
Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited — Research Highlights Gr
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Willis Towers Watson Public Limited Company (NASDAQ:WLTW), MyoKardia, Inc....
May 22, 2018 08:05 pm ET
MyoKardia Announces Pricing of Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,750,000...
May 21, 2018 04:01 pm ET
MyoKardia Announces Proposed Public Offering of Common Stock
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering...
May 21, 2018 07:30 am ET
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the design of its pivotal Phase 3 EXPLORER-HCM clinical trial...
May 10, 2018 04:30 pm ET
MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer,  will...
May 10, 2018 08:30 am ET
MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the start of the PIONEER open-label extension (OLE) study of...
May 08, 2018 04:01 pm ET
MyoKardia Reports First Quarter 2018 Financial Results
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported financial results for the quarter ended March 31, 2018....
May 03, 2018 04:01 pm ET
MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report first quarter 2018 financial and...
Apr 09, 2018 08:10 am ET
New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial — Consolidated Revenues, Company Growth, and Expectations for 2
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliance Resource Partners, L.P. (NASDAQ:ARLP), MyoKardia,...
Apr 04, 2018 08:30 am ET
MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of Taylor C. Harris as...
Mar 16, 2018 08:15 am ET
Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences — Renewed Outlook, Key Drivers of Gro
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), MyoKardia, Inc....
Mar 08, 2018 04:03 pm ET
MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results
Announced Achievement of Primary Endpoint and Additional Key Data from Low-Dose Mavacamten Cohort of PIONEER-HCM Phase 2 Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Mar 06, 2018 08:00 am ET
MyoKardia to Present at the Cowen and Company 38th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer,  will present at...
Mar 01, 2018 04:30 pm ET
MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018
SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report fourth quarter and...
Feb 14, 2018 04:30 pm ET
MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that senior management will participate in a fireside chat...
Feb 14, 2018 08:30 am ET
MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
Topline Results from First-in-Human Phase 1 Study of MYK-491 in Healthy Volunteers Demonstrated Tolerability and Increased Contractility
Jan 19, 2018 08:30 am ET
MyoKardia Announces Appointment of Cynthia Ladd as General Counsel
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the expansion of its executive committee with...
Jan 03, 2018 04:30 pm ET
MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, is scheduled...
Nov 15, 2017 08:00 am ET
Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, presented data that further elucidates the mechanism of action...
Nov 13, 2017 07:15 pm ET
MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, presented results from testing a novel machine learning algorithm intended to identify patients with obstructive hypertrophic cardiomyopathy (oHCM) during a late-breaker session at the American Heart Association (AHA) Scientific Sessions.  ...
Nov 13, 2017 07:15 pm ET
MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor
Digital Health Data from Substudy of PIONEER-HCM Presented in Late-Breaker at American Heart Association Scientific Sessions
Nov 02, 2017 04:02 pm ET
MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress
Received FDA Feedback for Mavacamten Registration Program in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Nov 01, 2017 08:00 am ET
MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that company research will be presented...
Sep 18, 2017 12:45 pm ET
MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients were presented at the Heart Failure Society of America (HFSA)’s 21st Annual Scientific Meeting in Dallas, TX....
Aug 07, 2017 04:01 pm ET
MyoKardia Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering of 3,500,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option to purchase an additional 525,000 shares of common stock at the public offering pric...
Aug 07, 2017 07:19 am ET
MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress
Positive Topline Results in First Patient Cohort of Phase 2 PIONEER-HCM Study...
Apr 18, 2017 08:30 am ET
MyoKardia Appoints David Meeker, M.D., to Board of Directors
SOUTH SAN FRANCISCO, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of David Meeker, M.D., to the Company’s board of directors....
Dec 01, 2016 08:00 am ET
MyoKardia Announces Appointment of Marc Semigran, M.D., as Chief Medical Officer
Former Medical Director of the Heart Failure and Cardiac Transplant Program at Massachusetts General Hospital to Lead Clinical Development...
Nov 07, 2016 08:00 am ET
MyoKardia Reports Progress on Clinical Programs and Third Quarter 2016 Financial Results
Dosing in Phase 2 PIONEER-HCM trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Under Way; Pathway to Registration Outlined             MYK-491 Dilated Cardiomyopathy Candidate Set to Enter Clinic in First Half of 2017...
Nov 02, 2016 08:00 am ET
MyoKardia Announces Dosing of First Patient in Phase 2 PIONEER-HCM Study of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
         Pilot Study Designed to Enable Progression to Larger Phase 2 Trial to Finalize Dosing and Endpoints Prior to Single Pivotal Study...
Oct 31, 2016 08:00 am ET
MyoKardia to Present at Two Upcoming Investor Conferences in November 
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, will participate in two upcoming investor conferences in November. Following are details for each presentation:...
Oct 03, 2016 04:30 pm ET
MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the closing of its previously announced underwritten public offering of 4,370,000 shares of common stock, at the public offering price of $15.00 per share, which included 570,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares. All of the shares in the offering were offered by MyoKardi...
Sep 27, 2016 06:47 pm ET
MyoKardia Announces Pricing of Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,800,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase up to an additional 570,000 shares of common stock on the same terms and conditions....
Sep 26, 2016 04:48 pm ET
MyoKardia Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced an underwritten public offering of 3,800,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option to purchase up to an additional 570,000 shares of common stock at the public offering price, less the underwriting discoun...
Sep 21, 2016 07:00 am ET
Sep 14, 2016 08:45 am ET
MyoKardia to Host R&D Day on September 21
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, will host a Research and Development (R&D) Day for analysts and investors on Sept. 21, 2016, at 8:30 a.m. ET in New York City....
Sep 01, 2016 04:30 pm ET
MyoKardia to Present at 2016 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, will present at the 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016, at 2:55 PM Eastern Time. The conference is being held at the Westin Waterfront Hotel in Boston....
Aug 10, 2016 08:30 am ET
MyoKardia to Present at the 2016 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that members of the Company management team will present at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 2:30 PM Eastern Time. The conference is being held at Le Parker Meridien Hotel in New York City....
Aug 09, 2016 08:30 am ET
MyoKardia Reports Second Quarter 2016 Financial Results and Continued Progress on Clinical Programs
MYK-461 Phase 2 PIONEER-HCM Study to Initiate in Second Half of 2016...
Jul 14, 2016 08:30 am ET
SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the Proceedings of the National Academy of Sciences of the United States of America. The article is the first to examine data from SHaRe, or the Sarcomeric Human Cardiomyopathy Registry, and demonstrates the power of combining clinical, genetic and structural data to gain insight into hypertrophic cardiomyopathy (...
Jul 11, 2016 04:02 pm ET
MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
MYK-461 Data Suggest Favorable Safety Profile Up to 28 Days Dosing in Healthy Volunteers and Reduction in Excess Cardiac Contractility in All HCM Patients Studied...
May 16, 2016 07:30 am ET
MyoKardia to Present at 2016 UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that members of the Company management team are scheduled to present at the 2016 UBS Global Healthcare Conference on Monday, May 23, at 4:00 PM Eastern Time. The conference is being held May 23-25 at the Grand Hyatt New York in Manhattan....
May 12, 2016 07:30 am ET
MyoKardia Reports First Quarter 2016 Financial Results and Operational Progress
SOUTH SAN FRANCISCO, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported business highlights and financial results for the first quarter ended March 31, 2016....
May 02, 2016 07:30 am ET
MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
SOUTH SAN FRANCISCO, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for MYK-461 for treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a subset of hypertrophic cardiomyopathy (HCM)....